Prevents elevation of arterial CO2 tension during the administration of oxygen. Sold as Dopram. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 16, 2026, FDA lists 3 applications for Doxapram Hydrochloride (sold as Dopram), first approved Jun 23, 1965, with 0 new uses approved and 0 published complete response letters.
| the Effect of Doxapram on Diaphragmatic Excursion(DE) During Weaning From Mechanical Ventilation.Mechanically Ventilated ICU Patients, Diaphragm Excursion · Kasr El Aini Hospital | Phase 4 | Not yet recruiting | Jun 9, 2026 |
| Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing TrialCOPD, Mechanical Ventilation · Cairo University | — | Recruiting | Jun 15, 2025 |
| Doxapram Therapy in Preterm Infants (DOXA Trial)Apnea of Prematurity, Respiratory Insufficiency · Erasmus Medical Center | Phase 3 | Recruiting | Jun 12, 2020 |
| Jun 23, 1965 | DopramNDA 14879 · New molecular entity | Hikma | 31 | Marketed |
| Jan 30, 1992 | Doxapram HydrochlorideANDA 73529 | Watson Labs | 3 | Discontinued |
| Jan 10, 2003 | Doxapram HydrochlorideANDA 76266 | Chartwell Injectable | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA